Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Takeda provides update on Exkivity (mobocertinib) for epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive NSCLC

Written by | 9 Oct 2023

Takeda announced that, following discussions with the FDA, it will be working with the FDA towards a voluntary withdrawal of Exkivity (mobocertinib) in the U.S. for adult patients… read more.

Publication of phase III FRESCO-2 results evaluating fruquintinib in patients with previously treated colorectal cancer in The Lancet – Takeda and HutchMed

Written by | 25 Jun 2023

Takeda and HUTCHMED (China) Limited announced that results of the Phase III FRESCO2 study evaluating fruquintinib in patients with previously treated metastatic colorectal cancer (CRC) were published in… read more.

FDA approval to expand the use of HYQVIA to treat primary immunodeficiency in children – Takeda

Written by | 2 Jun 2023

Takeda announced that the FDA has approved a supplemental biologics license application (sBLA) to expand the use of HYQVIA to treat primary immunodeficiency (PI) in children 2-16 years… read more.

Phase III HELP study of Takhzyro shows long-term safety and efficacy in Hereditary Angioedema – Takeda

Written by | 25 Jul 2021

Takeda Pharmaceutical announced results from two final analyses from the Phase III HELP (Hereditary Angioedema Long-term Prophylaxis) Study Open-label Extension (OLE), which evaluated the long-term safety (primary endpoint)… read more.

ICML 2017: How will Hodgkins lymphoma be managed in 2020?

Written by | 11 Jul 2017

By Maria Dalby (article) and Esther Drain (interviews) Not only is the treatment ‘landscape’ in Hodgkin lymphoma (HL) changing rapidly both in the first-line and relapsed/refractory setting, but… read more.

ISH/BSH 2016: Professor Philippe Moreau from Nantes in France reviewed the rationale for the new diagnostic criteria and highlighted the gaps in current risk models for stratifying the risk of progression to MM… Also included article entitled ‘High-risk smouldering myeloma’

Written by | 2 Jun 2016

High-risk smouldering myeloma by Maria Dalby Professor Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, France Subsequent to the publication of updated diagnostic criteria for MM in 2014,1 MM clinicians have… read more.

ISH/BSH 2016: Advances in our understanding of clonal evolution in MM: where are we now?

Written by | 2 Jun 2016

Professor Keith Stewart, Mayo Clinic, Scottsdale, AZ, USA. by Maria Dalby: The dramatic improvement in MM survival in the last 40 years is largely linked to the introduction… read more.

ESC Report 2013 – Alogliptin treatment shows no increase cardiovascular risk in Acute Coronary Syndrome

Written by | 26 Sep 2013

by Bruce Sylvester – Alogliptin treatment of patients with type 2 diabetes and with high cardiovascular risk due to recent acute coronary syndromes has led to similar rates… read more.

ESC 2013 Report – Low BMI is a risk factor for CVD in hypertensive patients with diabetes

Written by | 25 Sep 2013

Low BMI is a risk factor for CVD in hypertensive patients with diabetes, according to research presented at the ESC Congress today by Dr Takanori Nagahiro from Japan…. read more.

Green light for new medicines

Written by | 5 Sep 2013

EMA Highlights by Gary Finnegan – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has a new member: Ivana Mikacic has been nominated by Croatia which… read more.

Ganitumab disappoints in pancreatic cancer: Amgen halts Phase III Study

Written by | 3 Sep 2012

In a press release on August 8, 2012, Amgen announced that the company was halting a late-stage trial of its monoclonal antibody IGF-1 receptor antagonist ganitumab (AMG-479).

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.